Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Early menopause contributes to aromatase inhibitor-associated bone loss (CROSBI ID 662991)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Bojanić, Kristina ; Smolić, Martina ; Ivanac, Gordana ; Štimac, Damir ; Sikora, Miroslav ; Arambašić-Curić, Darija ; Smolić, Robert ; Kuna, Lucija Early menopause contributes to aromatase inhibitor-associated bone loss. 2018. doi: 10.1594/ecr2018/C-0318

Podaci o odgovornosti

Bojanić, Kristina ; Smolić, Martina ; Ivanac, Gordana ; Štimac, Damir ; Sikora, Miroslav ; Arambašić-Curić, Darija ; Smolić, Robert ; Kuna, Lucija

engleski

Early menopause contributes to aromatase inhibitor-associated bone loss

Breast cancer (BC) is the most prevalent cancer in the world with the incidence of 1.67 million in 2012. It is the most common cancer site with 26 % of all cancer sites in females. Treatment of BC is multidisciplinary and includes surgery, radiation, chemotherapy and adjuvant endocrine therapy in cases of hormone receptor (HR)-positive BC.Data from several clinical trials have shown that aromatase inhibitor- associated bone loss (AIBL) at the lumbar spine and hip surpass the gradual bone loss of 1% per year observed in healthy postmenopausal women (7-10). Third-generation AIs (exemestane, letrozole, and anastrozole), as potent inhibitors of estrogen production, have demonstrated superior efficacy and better overall safety in the adjuvant treatment of ER- positive BC, compared with the SERM (11, 12). However, AIs reducing the conversion of steroids to estrogen, consequently lower estrogen levels, increase bone turnover and result in the loss of bone mass. AIBL occurs at a rate of 2-3 fold higher than bone loss in healthy, age-matched postemopausal controls, resulting in significantlly higher incidence of fractures (13).Our results are in accordance with other recent studies and support the fact that during menopause the physiological reduction in ovarian production of estrogen is associated with rapid bone loss in the first 4- 8 years and after menopause residual estrogen levels are important for maintaining bone density (13).

Osteoporosis, Drugs / Reactions, Demineralisation-Bone, Treatment effects, Comparative studies, Oncology, Breast, Bones, Absorptiometry / Bone densitometry

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2018.

objavljeno

10.1594/ecr2018/C-0318

Podaci o matičnoj publikaciji

Podaci o skupu

The European Congress of Radiology(ECR)

poster

27.02.2018-03.03.2018

Beč, Austrija

Povezanost rada

Temeljne medicinske znanosti

Poveznice